🔎 Trials Near Me

Inicio › Enfermedad de Crohn › Ohio

Ensayos clínicos de Enfermedad de Crohn en Ohio

30 estudios sobre Enfermedad de Crohn buscan participantes en Ohio.

Ciudades en Ohio

Texto oficial del estudio (inglés)

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • Great Lakes Gastroenterology Research, LLC ( Site 5016), Mentor
ReclutandoFase 3
Edades de 16 a 80 · Todos los sexos · Actualizado el 2 oct 2026 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 2 oct 2026 · NCT07697456

Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease

  • UH Minoff Health Center, Chagrin Falls
  • University Hospitals Cleveland Medical Center, Cleveland
  • UH Westlake Health Center, Westlake
ReclutandoSe aceptan voluntarios sanos
Edades de 18 a 75 · Todos los sexos · Actualizado el 1 oct 2026 · NCT07852273

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • Gastro Health Research - Cincinnati, Cincinnati
  • DSI Research Northridge LLC, Dayton
  • Gastro Health Research - Liberty Township, Liberty Township
  • y 3 más
ReclutandoFase 4
Edades de 18 a 80 · Todos los sexos · Actualizado el 30 sept 2026 · NCT06581328

Non-nutritive Sweeteners in Inflammatory Bowel Disease

  • UH Minoff Health Center, Chagrin Falls
  • University Hospitals Cleveland Medical Center, Cleveland
  • UH Westlake Health Center, Westlake
ReclutandoSe aceptan voluntarios sanos
Edades de 18 a 70 · Todos los sexos · Actualizado el 25 sept 2026 · NCT07769437

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • University of Cincinnati /ID# 265589, Cincinnati
  • The Ohio State University /ID# 265577, Columbus
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 25 sept 2026 · NCT06548542

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  • Great Lakes Gastroenterology Research, LLC, Mentor
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07499232

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

  • Cincinnati Children's Hospital Medical Center, Cincinnati
ReclutandoFase 3
Edades de 3 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06663332

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  • Great Lakes Gastroenterology Research, LLC, Mentor
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 25 sept 2026 · NCT06233461

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
ReclutandoFase 3
Edades de 18 a 70 · Todos los sexos · Actualizado el 24 sept 2026 · NCT06937099

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT03816345

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology & Hepatology Specialists, Inc.-Site nUmber: 8400139, Canton
  • University Hospitals Cleveland Medical Center-Site Number: 8400073, Cleveland
  • Ohio Gastroenterology Group Inc.-8400006, Columbus
  • y 5 más
ReclutandoFase 3
Edades de 16 a 80 · Todos los sexos · Actualizado el 23 sept 2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Ohio Gastroenterology Group Inc.-Site Number: 8400006, Columbus
  • Medical Associates Research Group-Site Number: 8400063, Columbus
  • OSU Wexner Medical Center-Site Number: 8400077, Columbus
  • y 1 más
ReclutandoFase 3
Edades de 16 a 80 · Todos los sexos · Actualizado el 23 sept 2026 · NCT07184944

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

  • Cleveland Clinic - Cleveland /ID# 256453, Cleveland
ReclutandoFase 3
Edades de 2 a 17 · Todos los sexos · Actualizado el 23 sept 2026 · NCT05995353

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

  • University of Cincinnati, Cincinnati
  • Ohio Gastroenterology group, Inc., Columbus
  • Great Lakes Gastroenterology Research, LLC, Mentor
  • y 1 más
ReclutandoFase 4
Edades de 18 a 70 · Todos los sexos · Actualizado el 9 sept 2026 · NCT06045754

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  • Great Lakes Gastroenterology Research, LLC, Mentor
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT07577843

Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD

  • Cleveland Clinic, Cleveland
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 ago 2026 · NCT07680283

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  • Childrens Medical Center, Dayton
ReclutandoFase 3
Edades de 2 a 17 · Todos los sexos · Actualizado el 24 ago 2026 · NCT05509777

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

  • University of Cincinnati, Cincinnati
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT07237516

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  • UH Cleveland Medical Center /ID# 262188, Cleveland
ReclutandoFase 3
Edades de 2 a 17 · Todos los sexos · Actualizado el 24 jun 2026 · NCT06332534

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • University Children's Clinic, Cleveland
  • Cleveland Clinic, Cleveland
ReclutandoFase 3
Edades de 2 a 17 · Todos los sexos · Actualizado el 22 jun 2026 · NCT06405087

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • UH/Rainbow Babies and Children's Hospital, Cleveland
  • Nationwide Children's Hospital, Columbus
ReclutandoFase 4
Edades de 6 a 17 · Todos los sexos · Actualizado el 27 may 2026 · NCT05781152

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
ReclutandoFase 3
Edades de 2 en adelante · Todos los sexos · Actualizado el 7 may 2026 · NCT05442567

Precise Infliximab Exposure and Pharmacodynamic Control

  • Cincinnati Children's Hospital, Cincinnati
  • Cleveland Clinic Children's Hospital, Cleveland
  • Nationwide Children's Hospital, Columbus
ReclutandoFase 2/3
Edades de 6 a 22 · Todos los sexos · Actualizado el 5 may 2026 · NCT05660746

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

  • University Hospitals Cleveland Medical Center, Cleveland
ReclutandoFase 3
Edades de 2 a 17 · Todos los sexos · Actualizado el 5 may 2026 · NCT04779320

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  • OSU Inflammatory Bowel Disease Center, Hilliard
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 27 abr 2026 · NCT06456593

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, Cincinnati
  • Mirador Therapeutics Selected Site, Liberty Township
ReclutandoFase 2
Edades de 18 a 80 · Todos los sexos · Actualizado el 12 mar 2026 · NCT07113522

Treatment of Moderate to Severe Refractory Crohn's Disease

  • Cleveland Clinic, Cleveland
ReclutandoFase 1/2
Edades de 18 a 65 · Todos los sexos · Actualizado el 10 dic 2025 · NCT06721962

Evaluation of the SMART IBD App in Pediatric IBD

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Reclutando
Edades de 13 a 17 · Todos los sexos · Actualizado el 21 nov 2025 · NCT07195123

Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy

  • Cleveland Clinic Foundation, Cleveland
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2025 · NCT06670638

De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.